David M. Hughes, PharmD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

PharmD, Albany College of Pharmacy





Observational Study of Fostamatinib as Second Line Therapy in Adult Patients with Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy.
10/21/2020 - 10/20/2023 (PI)
Rigel Pharmaceuticals, Inc.


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Patel JV, Hughes DM, Ko NY. OPTIMAL Breast Cancer Care: Effect of an Outpatient Pharmacy Team to Improve Management and Adherence to Oral Cancer Treatment. JCO Oncol Pract. 2023 Mar; 19(3):e306-e314.View Related Profiles. PMID: 36480784; DOI: 10.1200/OP.22.00135;
     
  2. Famularo DE, Koloski J, Marathe J, Au A, Hamilton S, Mordino J, Hughes DM. Pharmacist-driven assessment and prescribing of COVID-19 therapeutics: A large, tertiary academic medical center's experience. Am J Health Syst Pharm. 2022 Oct 21; 79(21):1889-1893.View Related Profiles. PMID: 35917116; PMCID: PMC9384582; DOI: 10.1093/ajhp/zxac213;
     
  3. Hughes DM, Mordino J. Pharmacist responsiveness and readiness for oral antivirals for COVID-19: A rebuttal to the AMA statement regarding the Biden administration's test-to-treat plan. J Am Pharm Assoc (2003). 2022; 62(4):1162-1164. PMID: 35450832; PMCID: PMC8971105; DOI: 10.1016/j.japh.2022.03.023;
     
  4. Hughes DM, Henshaw L, Blevins F, Edwards C, Lerner A, Sloan JM, Sanchorawala V. Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clin Lymphoma Myeloma Leuk. 2022 Aug; 22(8):566-568.View Related Profiles. PMID: 35367193
     
  5. Hughes DM, Toste C, Nelson C, Escalon J, Blevins F, Shah B. Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series. J Adv Pract Oncol. 2021 Jul; 12(5):508-517.View Related Profiles. PMID: 34430061; PMCID: PMC8299792; DOI: 10.6004/jadpro.2021.12.5.6;
     
  6. Hughes DM, DeMari S, Hassan H, Sanchorawala V, Sloan JM. Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):e460-e463.View Related Profiles. PMID: 33716055
     
  7. Hughes DM, Staron A, Sanchorawala V. A pharmacist's review of the treatment of systemic light chain amyloidosis. J Oncol Pharm Pract. 2021 Jan; 27(1):187-198.View Related Profiles. PMID: 33028132
     
  8. Hughes DM, Goswami S, Keizer RJ, Hughes MA, Faldasz JD. Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population. J Antimicrob Chemother. 2020 02 01; 75(2):434-437. PMID: 31670812
     

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 8 publications over 3 distinct years, with a maximum of 4 publications in 2022

YearPublications
20202
20212
20224


Umit Tapan, MD, David Hughes, PharmD, BCOP, Jasmine Patel, PharmD, BCOP and Bhavesh Shah, RPh, BCOP Receive Grant From Pfizer

BU Hematology & Oncology 1/1/2021
Contact for Mentoring:

830 Harrison Ave
Boston MA 02118
Google Map

617.638.5952
Download vCard

Hughes's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (38) concept(s)
_
Media Mentions
_
Co-Authors
See all (8) people
_
Similar People
See all (60) people
_
Same Department
Search Department